Pulmonary hypertension: Its assessment and treatment

Thorax

Volumn 54, Issue SUPPL. 2, 1999, Pages

  Brij, Seema ^a   Peacock, Andrew J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BERAPROST; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; UNCLASSIFIED DRUG; UNIPROST; WARFARIN;

ABDOMINAL PAIN; ARTERIAL PRESSURE; BRONCHOSPASM; CLINICAL TRIAL; DIARRHEA; DRUG COST; HEADACHE; HOT FLUSH; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; NAUSEA; ORAL DRUG ADMINISTRATION; OXYGEN THERAPY; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX PAIN; VASODILATATION; VOMITING;

EID: 0032788850     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.2008.s28     Document Type: Review

References (34)

1. 1 McDonnell P, Toye P, Hutchins G. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983;127:437-41.
2. 2 Rich S, Dantzker DR, Ayres SM. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
3. 3 Petitpretz P, Brenot F, Azarian R. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994;89:2722-7.
4. 4 Sitbon O, Humbert M, Jagot J, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
5. 5 McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338: 273-7.
6. 6 Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
7. 7 Zobel G, Dacar D, Rodl S, et al. Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets. Pediatr Res 1995;38:198-204.
8. 8 Pepke-Zaba J, Higgenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-4.
9. 9 Sitbon O, Brenot F, Denjean A. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995;151:384-9.
10. 10 Walmrath D, Schermuly R, Pilch J, et al. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 1997;10:1084-92.
11. 11 Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1983;66:334-8.
12. 12 Morgan JM, McCormack DG, Griffiths MJD, et al. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991;84: 1145-9.
13. 13 Jolliet P, Bulpa P, Thorens J, et al. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997;52:369-72.
14. 14 Jones DK, Higgenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J 1984;57:270-8.
15. 15 Mikhail G, Gibbs J, Richardson M, et al. An evaluation of nebulised prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997;18:1499-504.
16. 16 McCormack DG, Clarke B, Barnes CJ. Characterization of adenosine receptors in human pulmonary arteries. Am J Physiol 1989;256:H41-6.
17. 17 Bush A, Busst CM, Clarke B, et al. Effect of infused adenosine on cardiac output and systemic resistance in normal subjects. Br J Clin Pharmacol 1989;27:665-8.
18. 18 Nootens M, Schrader B, Kaufmann E, et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995;107:54-7.
19. 19 Murad F, Arnold W, Mittal CK, et al. Properties and regulation of guanylate cyclase and some proposed functions for cyclic GMP. Adv Cyclic Nucleotide Res 1979;11:175-204.
20. 20 Ignarro LJ, Burke TM, Wood KS. Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. J Pharmacol Exp Ther 1984;228:682-90.
21. 21 Robbins IM, Christman BW, Newman JH, et al. A survey of diagnostic practices and the use of epoprostenol in patients with pulmonary hypertension. Chest 1998;114:1269-75.
22. 22 Farber HW, Karlinskz JB, Faling LJ. Fatal outcome following nifedipine for primary pulmonary hypertension. Chest 1983;83:708-9.
23. 23 Aromatorio GJ, Uretsky BF, Reddy PS. Hypotension and sinus arrest with nifedipine in pulmonary hypertension. Chest 1985;87:265-7.
24. 24 Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on primary pulmonary hypertension. Am Rev Respir Dis 1989;140:1623-30.
25. 25 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
26. 26 Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;681-6.
27. 27 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxaemic chronic obstructive lung disease. Ann Intern Med 1980;93:391-8.
28. 28 Barst RJ, Rubin L, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
29. 29 Torley HI, Madhok R, Cappell HA, et al. A double-blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800-4.
30. 30 Pasque MK, Kaiser LR, Dresler CM, et al. Single lung transplantation for pulmonary hypertension: technical aspects and immediate haemodynamic results. J Thorac Cardiovasc Surg 1992;103:475-81.
31. 31 Higgenbottam TW, Spiegelhalter D, Scott JP. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1983;70:366-70.
32. 32 Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995;91:2028-35.
33. 33 Higgenbottam TW, Ward S, Brennan A, et al. Working group on accurate purchasing prostacyclin and iloprost in the treatment of pulmonary hypertension. Guidance for purchasers. 1997: 97/02 (abstract).
34. 34 Rolla G, Colagrande P, Brussino L, et al. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension. Lancet 1998;351:1491-2.